QMS: Whack-a-mole
Quality Systems
When QMS workloads outgrow the team, “closure sprints” and shiny eQMS tools create the illusion of control, but only root causes and meaningful KPIs stop the
cycle.
QMS: 30-Day Deployment
Quality Systems
A structured set of weekly sprints builds the phase-appropriate QMS foundations sponsors need for clinical submissions, fast, bespoke, and workable, with committed client engagement.
Interim Leadership
Leadership
When a leader exits and the room wobbles, interim leadership steadies people, re-aligns delivery, and keeps leadership updates visible and defensible until a clean handover.
The Deal Isn’t the Deck
Diligence
The Deal Isn’t the Deck: In fast pharma deals, value sits in technical reality, systems, facilities and people, so diligence must surface red flags and options early enough to change the deal or the first 90-day plan.
Don’t Blame the Operator
Aseptic Assurance
Don’t Blame the Operator: Aseptic failures rarely start with operators, so a proper aseptic assessment follows controls from dock to dock, challenges “Grade A is bulletproof,” and leaves a roadmap the site can run.
AI Deployment: If You Can’t Explain It, You Can’t Keep It
Artificial Intelligence
AI and ML only create value in regulated pharma when intended use, governance, validation, monitoring, and human accountability are clear and
defendable.
The CDMO (Supplier) Isn’t the Risk. The Interface Is
Vendor Assurance
Vendor assurance is an operating model across suppliers, where clear boundaries, escalation, and tiered oversight prevent supply shocks becoming programme failures.
Integration: Where Good Plans Go to Die
Company and System Integration
Integrations fail at interfaces, data equivalence, ownership gaps, and culture drift, so an Integration Master Plan must manage boundaries to protect supply and compliance.
Inspection Readiness: The Inspector Is Not the Problem
Inspections
Inspection outcomes are decided by everyday habits, evidence quality, and human performance under pressure, so readiness means “how we work normally,” not a pre-inspection sprint.
Cold Chain: Hot Consequence
GDP and Supply Chain
A practical guide to autologous vein-to-vein cold chain control, showing how to select and govern logistics vendors and build defensible Chain of Identity and Chain of Custody so shipments do not fail at the handover.
CTA & IND: The Submission Is Not the Science
Clinical Trials
A practical playbook for building US INDs and converting them into EU CTAs and IMPDs through CTIS, aligning CTD content, CMC readiness, sponsor oversight, timelines, and regulator engagement to protect trial start dates.
